Bicara (BCAX) Q1 2026 Earnings Call Summary
Bicara reported $539.8 million in cash and equivalents as of the end of Q1 2026, bolstered by a recent public offering that raised $161.8 million. Operating expenses increased due to higher clinical trial costs, manufacturing expansion, and personnel-related expenses.
Tickers: $BCAX
Topics: clinical_trials financial_results pharma